The features of three babies with lethal perinatal osteogenesis imperfecta resulting from the substitution of glycine by arginine in the pro cal(I) chain of type I procollagen were studied. The babies were heterozygous for this substitution at residue 391 in case 1 (OI24), 667 in case 2 (OI51), and 976 in case 3 (OI30). They were all small, term babies who died soon after birth. The ribs were broad and continuously beaded in OI24, discontinuously beaded in OI51, and slender with few fractures in OI30. Biochemical heterogeneity has also been noted in the various types and subtypes of 01 with the characterisation of a range of mutations of the COLlAl gene that encodes the pro al(I) chain and the COL1A2 gene that encodes the pro a2(I) chain of type I collagen.3 As a result, the opportunity now exists to examine the relationships between the genotypes and clinical phenotypes of 01.
Biochemical heterogeneity has also been noted in the various types and subtypes of 01 with the characterisation of a range of mutations of the COLlAl gene that encodes the pro al(I) chain and the COL1A2 gene that encodes the pro a2(I) chain of type I collagen.3 As a result, the opportunity now exists to examine the relationships between the genotypes and clinical phenotypes of 01.
We have reported the substitution of glycine by arginine at different sites in the 1014 residue triple helical domain of the pro al (I) chain of type I collagen in three babies with lethal perinatal (type II) OI.3 5 6 The babies were heterozygous for this substitution at residue 391 in OI24, 667 in OI51, and 976 in OI30. Our previous studies have also shown abnormal collagen metabolism by cultured fibroblasts and abnormal collagen composition of tissues from these babies.7 8 The principal findings were slow electrophoretic migration of type I collagen chains owing to overmodification of lysine residues that were amino terminal to the mutation.9 There were also abnormalities of collagen metabolism including decreased secretion, increased intracellular degradation, and decreased thermal stability. The amount of type I collagen was reduced in the dermis and bone. In this paper we describe the clinical and pathological features of these babies and correlate these findings with the biochemical abnormalities. Light microscopy showed that the dermis was thin when compared to normal age matched control dermis. The junction between the loose papillary and the dense reticular layers of the dermis was poorly defined. The collagen bundles were well formed and normally birefringent. Silver staining showed a decreased number of small, dark, argyrophilic fibres in the superficial dermis. Elastic fibres were decreased in size and in number. Electron microscopy showed marked dilatation of rough endoplasmic reticulum of fibroblasts in OI24 but not in OI51 or 0130. The major histological features of 01 bone included the paucity of matrix around the osteoblasts, the failure of maturation of osteoblasts, and the lack of lamellar bone and Haversian systems. These findings are likely to result from the effects of the mutations on the amount and quality of type I collagen, although the exact pathogenesis of these architectural and maturational abnormalities remains unclear.
van der Harten et al'2 reported that the histological appearances of the metaphysis correlated with the radiographical subtypes of type II OI. Thin calcified trabeculae were reported in cases of type IIA and IIB 01 while broader and irregularly arranged cartilaginous trabeculae were reported to be characteristic of type IIC OI. In contrast, we observed both patterns at different sites in the same patient. As a result, this difference in pattern is likely to be non-specific.
Many of the findings in the present study are in accordance with our previous biochemical results. The thinness of the dermis is consistent with its reduced concentration of type I collagen.8 Similarly, the reduced amount of bone is consistent with our previous findings of reduced amounts of type I collagen in this tissue. We also found an increased proportion of type III and V collagens that were localised to the non-calcified fraction of 01 bone.8 This fraction is likely to correspond to the marrow tissue which is abundant between the sparse trabeculae of woven bone.
Our previous studies also showed decreased thermal stability of the mutant collagen and increased intracellular degradation of collagen produced by cultured dermal fibroblasts. 7 18 In the present study of glycine substitutions by arginine in the al(I) chain, there is evidence of a gradient of bone modelling. While this proposal might indicate a gradient of severity of phenotype that is the reverse ofthat observed with glycine substitutions by cysteine, it should be noted that all of the substitutions of glycine by arginine were lethal. We are unable to determine whether 0124, with a birth weight of 2290 g and unmodelled bones owing to a substitution at residue 391, was more or less severely affected than OI30 with a birth weight of 1091 g, slender bones, and overmodelled bones owing to a substitution at residue 976.
These relationships have also been studied using site directed mutagenesis of a mouse COLlAl gene. Mutations, resulting in the substitution of glycine-859 by arginine or cysteine, were expressed in fibroblasts where they produced metabolic and electrophoretic changes that were identical to those seen in patients with the same substitutions at nearby positions. 19 When the cysteine mutant gene was expressed in transgenic mice it resulted in a lethal perinatal 01 phenotype that was almost identical to type IIA 01. The severity of the phenotype was related to the expression of the mutant gene. 19 Study of further 01 babies with defined mutations and the study of additional animal models of 01 produced by site directed mutagenesis of collagen genes should provide further insights into the factors involved in the phenotypic expression of type I collagen mutations. 
